#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Chronic recurrent urticaria, joint and bone pain, fever of unknown origin and monoclonal IgM = Schnitzler’s syndrome


Authors: Z. Adam 1;  R. Koukalová 2;  M. Krejčí 1;  Z. Čermáková 3;  E. Vetešníková 1;  L. Pour 1;  V. Sandecká 1;  M. Štork 1;  Z. Řehák 2;  E. Pourová 4;  A. Čermák 5;  Z. Král 1;  J. Mayer 1
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1;  Oddělení nukleární medicíny, centrum PET, RECAMO. Masarykův onkologický ústav v Brně 2;  Oddělení klinické biochemie FN Brno a Katedra laboratorních metod LF MU Brno 3;  Ambulance praktického lékaře pro dospělé, Pustiměř u Vyškova 4;  Urologická klinika LF MU a FN Brno 5
Published in: Transfuze Hematol. dnes,24, 2018, No. 2, p. 88-103.
Category:

Overview

Schnitzler’s syndrome is an acquired auto-inflammatory disease of as yet unclear origin. The Strasbourg criteria (non-infectious fever, chronic urticaria, changes in bone structure, leucocytosis, elevated inflammatory markers – CRP and the presence of monoclonal immunoglobulin mostly IgM, very rarely of IgG) were adopted to establish this diagnosis. First-line therapy for this disease involves blocking interleukin-1 effects. In practice, the interleukin-1 receptor antagonist, anakinra, is most commonly used. Currently, there have also been reports regarding the use of other interleukin-1 blockers, namely canakinumab and rilonacept. We are currently treating 5 men, median age at diagnosis 53 (42–60) years, with anakinra. Median duration of treatment is 56 (19–122) months. In all the patients, we began administration of anakinra at a dose of 100 mg once a day. Administration of 100 mg once a day, led to the complete resolution of symptoms in 4 patients, and a reduction by about 75 % in 1 patient. This patient required an increased dose of 2 ampoules per day when his symptoms intensified. After one year of treatment, one of the four patients whose symptoms had completely disappeared using the 100 mg daily dose required this same dose at an interval 48-hour hours. However, this patient does not tolerate further extension of the intervals between doses. We have not recorded any adverse effects of anakinra in the course of the treatment and no decline in the efficiency of anakinra has been observed: it acts as effectively now as it did at the beginning of treatment. The text discusses the differential diagnosis of Schnitzler syndrome.>

Key words:

Schnitzler’s syndrome – Adult Still’s disease – auto-inflammatory diseases – monoclonal gammopathy – interleukin 1 – anakinra – fever of unknown origin – FUO


Sources

1. Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaloïde?) Cas cliniques, n° 46 B. Journée Dermatologique d’Angers, 28 octobre 1972.

2. Schnitzler L, Schubert B, Boasson M, et al.  Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenström? Bull Soc Fr Dermatol Syphil 1974;81:363–366.

3. Schnitzler L, Hurez D, Verret JL. Urticaire chronique, ostéocondensation, macroglobulinémie. Cas princeps. Etude sur 20 ans. Ann Dermatol Venereol 1989;116:547–550.

4. Lipsker D, Veran Y, Grunenberger F, et al. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001;80:37–44.

5. de Koning HD, Bodar EJ, van der Meer JW. Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137–148.

6. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010;8:38–40.

7. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759–3764.

8. Claes K, Bammens B, Delforge M, et al. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol 2008;158:182–184.

9. Simon A, Asli B, Braun-Falco M, et al. Schnitzler syndrome: diagnosis, treatment and follow up. Alergy 2013;68:562–568.

10. Gusdorf, L Lipsker D. Schnitzler syndrome. Curr Rheumatol Rep 2017;19:46–50.

11. Adam Z. Krejčí M, Pour L, et al. Schnitzlerův syndrom – popis čtrnáctiletého průběhu nemoci a přehled informací o této nemoci. Vnitř Lék 2008;54:1140–1153.

12. Adam Z, Šedivá A, Koukalová R, et al. Schnitzlers syndrome, diferenciální diagnóza, přehled léčebných možností a popis 5 případů léčených anakinrou. Vnitř Lék 2016;62:713–727.

13. Cetkovská P, Benáková N. Autoinflamatorní syndromy s kožními projevy. Čes-slov Derm 2015;90:144–155.

14. Tichá M. Terapie autoinflamatorních onemocnění a periodických horeček. Alergie 2015;17:128–135.

15. Šedivá A. Nové poznatky a pokroky v oblasti primárních imunodeficiencí. Postgrad Med 2015;17:294–303.

16. Blažová K, Horáčková M, Horváth R. Kardiorenální syndrom při AA amyloidóze v důsledku kombinace dvou mutací genů pro periodické horečky. Aktuality v nefrologii 2013;19:127–130.

17. Doležalová P. Syndrom CINCA – nejzávažnější onemocnění ze skupiny kryopyrinopatií. Farmakoterapie 2012;8(Suppl. 1):8–9.

18. Šedivá A. Autoinflamatorní onemocnění v dermatologii. Čes-slov Derm 2012;2:239–243.

19. Šedivá A. Autoinflamatorní onemocnění a familiární středozemní horečka. Alergie 2012;14(Suppl. 2):26–30.

20. Šedivá A. Periodické horečky a autoinflamatorní onemocnění – klinický přístup. Postgrad Med 2012;14:174–179.

21. Šedivá A. Periodické horečky AU. Alergie 2009;11:P1–P16.

22. Šedivá A. Periodické horečky a další syndromy s poruchou regulace zánětlivé odpovědi. Čes-slov Pediat 2011;66:187–191.

23. Němcová D, Doležalová D, Brejchová I. Autoinflamatorní onemocnění kostí. Čes Revmatol 2010;18 :10–15.

24. Doležalová P, Król P, Němcová D. Autoinflamatorní onemocnění – přehled. Čes Revmatol 2010;18:144–145.

25. Cush JJ. Autoinflamatory syndromes. Dermatol Clin 2013;31:471–480.

26. Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. Clin Med (Lond) 2015;15:295–298.

27. Beer HD, Contassot E, Frech LE. The inflammasome in autoinflamatory disease with skin involvement. J Invest Dermatol 2014;134:1805–1810.

28. Valentin MG, Jamilloux Y, Iwaz Y, et al. Adult onset Sill´s disease. Autoimmunity reviews 2014;13:708–722.

29. Malegová J, Koen L, Horák P. Stillova nemoc dospělých, obtížná cesta k diagnóze přes horečku a výpotky nejasné etiologie. Vnitř Lék 2014; 60:520–526.

30. Skácelová M, Horák P. Stillova nemoc dospělých – kazuistika. Čes Revmatol 2012;20:198–202.

31. Skácelová M, Horák P. Stillova choroba dospělých. Postgrad Med 2015;17:391–394.

32. Houzarová A. Stillova nemoc. Referátový Výběr z Revmatologie 2007;47:1214–1216.

33. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992;19:424–430.

34. Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine 2002;81(3):194–200.

35. Ryan JG, de Koning HD, Beck LA, et al. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008;121:260–262.

36. De Koning HD, Schalkwijk J, Stoffels M, et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome. Arthritis Res Ther 2015;7:187–188.

37. De Koning HD, van Vlijmen-Willems IMJJ, Rodijk-Olthuis D, et al. Mast-cell interleukin-1beta, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler’s syndrome. Br J Dermatol 2015;173:448–456.

38. Noster R, de Koning HD, Maier E, et al. Dysregulation of proinflammatory versus anti-inflammatory human TH17 cell functionalities in the autoinflammatory Schnitzler syndrome. J Allergy Clin Immunol 2016;138:1161–1169.

39. Mulla E, Neame R. Delayed development of the IgM paraprotein in Schnitzler’s syndrome. Scand J Rheumatol 2015; 44:521–522.

40. De Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy 2014;4:41–43.

41. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009;88:23–31.

42. Broekaert SMC, Boer-Auer A, Kerl K, Herrgott I, et al. Neutrophilic epitheliotropism is a histopathological clue to neutrophilic urticarial dermatosis. Am J Dermatopathol 2016;38:39–49.

43. Lamprecht P. Adult-onset Still’s disease, Schnitzler syndrome, and autoinflammatory syndromes in adulthood. Z Rheumatol 2009;68:740–746.

44. Patel S, Sindher S, Jariwala S, et al. Chronic urticaria with monoclonal IgG gammopathy: a clinical variant of Schnitzler syndrome? Ann Allergy Asthma Immunol 2012;109:147–148.

45. Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972–2011). J Am Acad Dermatol 2012;67:1289–1295.

46. Flórez AF, Gallardo Agromayor E, García-Barredo R, at al. Radiological aid to clinical diagnosis of Schnitzler’s syndrome: multimodality imaging approach. Clin Rheumatol 2008;27:107–110.

47. Lee KY, Grattan CE. Intracostal neuralgia as a previously undescribed symptom of Schnitzler’s syndrome. Br J Dermatol 2012;167:1392–1393.

48. Terpos E, Asli B, Chistoulas D, et al. Increased angiogenesis and enhanced bone formation in patients with IgM Monoclonal gammopathy and urticarial skin rash: New insight into the biology of the Schnitzler syndrome. Haematologica 2012;97:1699–1703.

49. Niederhauser BD, Dingli D, Kyle RA. Imaging findings in 22 cases of Schnitzler syndrome: charakteristic paraartikular osteosklerosis and the hot knees sign differential diagnosis. Skeletal Radiol 2014;43:905–915.

50. Willekens I, Walgraeve N, Goethals L, et al. Correlative bone imaging in a case of Schnitzler´s syndrome a briew review of the literatura. Hell J Nucl Med 2015;18:71–73.

51. Jarůšková M, Bělohlávek O. Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states. Eur J Nucl Med Mol Imaging 2006;33:913–918.

52. Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 2013;68:562–568.

53. Gusdorf L, Asli B, Barbarot S,  et al. Schnitzler syndrome: validation and  applicability of diagnostic criteria in real-life patients. Allergy 2017;72:177–182.

54. Kotík L. Teploty nejasného původu Interní Med pro Praxi 2006;8:493–495.

55. Ferdová E, Záhlava J, Ferda J. Horečky nejasného původu, význam hybridního zobrazení 18F-FDG-PET/CT. Čes Radiol 2008;62:23–33.

56. Ahn MJ, Yu JE, Jeong J,  et al. A case of Schnitzler’s syndrome without monoclonal gammopathy-associated chronic urticaria treated with anakinra. Yonsei Med J  2018;59:154–157.

57. Gouveia AI, Micaelo M, Pierdomenico F, et al. Schnitzler Syndrome: A dramatic response to anakinra. Dermatol Ther (Heidelb) 2016;6:299–302.

58. Sönnichsen A, Saulite I, Mangana J, et al. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J Dermatolog Treat 2016;27:436–438.

59. Koch A, Tchernev G, Chokoeva AA, et al. Schnitzler syndrome responding to interleukin-1 antagonist anakinra. J Biol Regul Homeost Agents 2015;29(1 Suppl):19–21.

60. Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev 2014;13:1035–1041.

61. Pesek R, Fox R. Successful treatment of Schnitzler syndrome with canakinumab. Cutis 2014;94:E11–E12.

62. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 2013;72:1634–1638.

63. Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum 2013;42:413–416.

64. de Koning HD, Schalkwijk J, van der Meer JW, et al. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011;128:1352–1354.

65. Krause K, Tsianakas A, Wagner N, et al. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J Allergy Clin Immunol 2017;139:1311–1320.

66. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012;67:943–950.

67. Kluger N, Bessis D, Guillot B. Tocilizumab as a potential treatment in Schnitzler syndrome. Med Hypotheses 2009;72:479–480.

68. Krause K, Feist E, Fiene M, et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848–850.

69. Aouba A, Pressiat C, Pricopi M, et al. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone. Dermatol 2015;230:18–22.

70. Cascavilla N, Bisceglia M, D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int J Immunopathol Pharmacol 2010;23:633–636.

71. Murota H, Shoda Y, Ishibashi T, et al. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J Am Acad Dermatol 2009;61:1070–1075.

72. Eiling E, Möller M, Kreiselmaier I, et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007;57:361–364.

73. Ramadan KM, Eswedi HA, El-Agnaf MR. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol 2007;156:1072–1074.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#